Novo Nordisk CEO to Testify on High U.S. Prices for Ozempic and Wegovy

Senate hearing scheduled for September after Bernie Sanders' push for transparency on drug pricing disparities.

Lars Jorgensen will testify voluntarily, canceling the need for a subpoena vote.
Americans pay significantly more for Ozempic and Wegovy compared to other countries.
The Senate Committee on Health, Education, Labor, and Pensions will conduct the hearing.
Novo Nordisk attributes high prices to the U.S. healthcare system's complexities.
Previous efforts by Sanders have led to similar hearings with other pharmaceutical companies.